Merrill Lynch maintains Genzyme at neutral

Genzyme Corp. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating despite third-quarter results that beat estimates. Earnings per share were $0.61 versus Merrill Lynch estimates of $0.60 a share and consensus of $0.58 a share. Merrill Lynch said Genzyme's Renegal showed strength with sales of $107 million, over estimates of $103 million. Merrill Lynch said it is raising earnings per share estimates to $2.30 from $2.29 in 2005 in light of strong revenue and good expense control, but doesn't think results justify a buy rating. Shares of the Cambridge, Mass.-based biotechnology company were up $0.13, or 0.19%, at $69.45 on volume of 3,325,430 shares versus the three-month running average of 2,450,460 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.